• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Creative Bio-Peptides Inc.

Creative Bio-Peptides Inc.

  • Home
  • Company
    • Our Company
    • Our People
  • Science
    • Introduction
    • RECEPTIDES
    • Publications
  • Therapy Areas
    • Persistent Post-Surgical Pain
    • Parkinson’s Disease
    • Opioid Use Disorders
  • News
  • Contact
  • LinkedIn

CCR5 Antagonist RAP-103 Protects Synapses in Dementia

May 29, 2024

Synapse loss is the principal cause of cognitive decline in Alzheimer’s disease (AD) and related disorders ( LBD, ADRD). Many, if not all patients experience a “mixed-dementia”, caused by multiple toxic oligomers such as amyloid beta, tau, and alpha-synuclein in the brain, but also now being documented throughout the body. These individuals experience an accelerated disease. The first study [Kuhn, 2024] reports that RAP-103, a CCR5 antagonist, at exceedingly low concentrations, prevents amyloid beta destruction of synapses in cultured rodent and human neurons. A further study [Liz, 2024] showed that RAP-103 blocks the effects of alpha-synuclein on hippocampal neurons, spines, and synapses via CCR5 dependent pathways. These effects, if translated to people, are expected to slow, prevent, even reverse cognitive decline in multiple dementias, especially those with significant mixed etiologies.

Filed Under: Uncategorised

Primary Sidebar

Latest News

  • CCR5 Antagonist RAP-103 Protects Synapses in Dementia May 29, 2024
  • RAP-103 Inhibits Opioid-derived Dependence, Withdrawal and Respiratory Depression  Jul 19, 2022
  • RAP-103 Benefits in Pain Published Jul 14, 2022
  • BioHealth Innovation Press Release Features Creative Bio-Peptides Nov 30, 2021
  • A Conversation with CBO Michael Simon Apr 8, 2021
  • NIH SBIR AWARD FOR SYNAPSE PROTECTING TREATMENTS FOR ALZHEIMER’S DISEASE Sep 28, 2020
  • CREATIVE BIO-PEPTIDES RECEIVES NIH HEAL AWARD FOR OPIOID ABUSE DISORDERS Jan 20, 2020
  • CREATIVE BIO-PEPTIDES and LEIDOS AWARDED US DOD CONTRACT Jan 18, 2020

Read more news

Footer

Creative Bio-Peptides Inc.

Rockville, MD
USA  20854

  • LinkedIn

  • CCR5 Antagonist RAP-103 Protects Synapses in Dementia May 29, 2024
  • RAP-103 Inhibits Opioid-derived Dependence, Withdrawal and Respiratory Depression  Jul 19, 2022
  • RAP-103 Benefits in Pain Published Jul 14, 2022
  • BioHealth Innovation Press Release Features Creative Bio-Peptides Nov 30, 2021
  • A Conversation with CBO Michael Simon Apr 8, 2021
  • NIH SBIR AWARD FOR SYNAPSE PROTECTING TREATMENTS FOR ALZHEIMER’S DISEASE Sep 28, 2020
  • CREATIVE BIO-PEPTIDES RECEIVES NIH HEAL AWARD FOR OPIOID ABUSE DISORDERS Jan 20, 2020
  • CREATIVE BIO-PEPTIDES and LEIDOS AWARDED US DOD CONTRACT Jan 18, 2020

Read more news

Copyright © 2025 Creative Bio-Peptides Inc.